Evaluation of Prophylactic EGD versus Beta Blockade in Hepatocellular Carcinoma Patients on Anti-Angiogenic Cancer Treatments

Read full text Summarise with VIRAT
Authors: Panayiotis D. Kontoyiannis, Camila Ayerbe, Kok Hoe Chan, Sara Soliman, Victor I. Machicao, Julie Haewon Rowe
Cited by: 0
References: 7

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Panayiotis D Kontoyiannis,1 Camila Ayerbe,2 Kok Hoe Chan,3 Sara Soliman,4 Victor Machicao,5 Julie H Rowe4 1Department of Internal Medicine, The University of Southwestern Medical Center, Dallas, TX, USA; 2Department of Internal Medicine and Pediatrics, The University of Southwestern Medical Center, Dallas, TX, USA; 3Department of Medicine, CAMC Institute for Academic Medicine, Charleston Area Medical Center, Charleston, WV, USA; 4Department of Internal Medicine, Division of Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; 5Department of Internal Medicine, Division of Hepatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USACorrespondence: Julie H Rowe, Department of Internal Medicine, Division of Oncology, The University of Texas Health Science Center at Houston, 6410 Fannin St., Ste. 830, Houston, TX, 77030, USA, Email Julie.Rowe@uth.tmc.edu

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Gastrointestinal Bleeding Diagnosis and Treatment Gastric Cancer Management and Outcomes

Publication details

Journal / source
Journal of Hepatocellular Carcinoma
Volume
Volume 13
Pages
1–10
Publication date
1 March 2026
Language
EN